5-7 Nov 2018
& 14-16 May 2019 , 4-6 Nov 2019
A 3 day accelerated management programme, designed specifically for Pharmaceutical / Biotechnology professionals and also applicable Medical Device / Animal Health Industries, to give you the high- performance management skills of an MBA. This intensive course will help you to translate your learning into new behaviours and improvements in your capability and performance and will work through live issues impacting on the industry and on you directly. The individual and group exercises will focus on Bio/Pharmaceutical /Generic MBA case studies, and also on your own challenges and examples. The case studies will help also give the ‘feel’ of a full MBA and help you understand more about the strategies used in todays Pharmaceutical and associated industries.
Please note that there will also be some case study reading to do each evening (approximately 35 mins)
A residential rate to include 2 nights accommodation is also available when booking.
Working in the highly competitive Bio / Pharmaceutical Industry, with ever-increasing change and pressure, is probably one of the most challenging managerial roles of any Industry today. This course has been especially designed to help you transcend these challenges by training you to become equipped to see the bigger picture in all aspects of your role. It will help you build your management skills for the future and prepare you to fulfill your ambitions.
The Pharma 3 day Mini MBA accelerated management programme is a distillation of the most valuable parts of an MBA, as applied to the Bio/Pharmaceutical industry. It will provide you with practical management tools to apply in the workplace, as well as giving a real taste of an MBA course with the Pharmaceutical case studies from business schools
The skills you will improve include:-
A “must attend” for Professionals in the Bio / Pharmaceutical / Medical Device / Animal Health Industries wishing to develop their business management skills for more senior levels and beyond more technical skills. It will also help anyone thinking of studying for an MBA who would like an idea of what is involved. It is particularly beneficial to attend with a colleague to maximise the practical learning.
09.00 Registration and coffee
09.30 Mini MBA Module 1
17.00 Close of day one
09.30 Mini MBA Module 2
17.00 Close of day two
09.30 Mini MBA Module 3
Leading Change and Project Management in the Bio/Pharma Industry
Managing Innovation in the Pharmaceutical Industry
MINI MODULE – POST COURSE DEVELOPMENT
Practical application / review
16.30 Close of day three
Laura Brown (5-7 Nov 2018, 14-16 May 2019)
Dr Laura Brown MBA, BSc,PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff. She has more than 20 years’ experience of quality assurance in the pharmaceutical industry and has worked for several companies, including GSKs Hoechst Marion Roussel, Farmitalia and Phoenix International. She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry. She regularly writes on pharmaceutical regulatory issues including “The Planning of International Drug Development”, in the Clinical Research Manual, Euromed and the “Impact of Brexit”, RQA Journal 2017.
Leela Barham (5-7 Nov 2018)
BSc (Economics), MSc (Health Economics)
Leela Barham is an independent health economist and policy expert working on a freelance basis. This follows 7 years at a specialist economic consulting firm working in a small dedicated health and pharmaceutical team.
She has more than 10 years experience in the pharmaceutical industry – both at home and abroad – and has worked for all stakeholders in the health care system ranging from patient organisations, the National Health Service, health insurers, and the pharmaceutical industry.
She has particular expertise in public and patient involvement, Patient Access Schemes/risk sharing schemes, the Cancer Drugs Fund, policy on Health Technology Assessment (HTA), and the Pharmaceutical Price Regulation Scheme (PPRS). She regularly writes on hot topics affecting the industry for Pharmaceutical Executive, Pharmaphorum and EyeforPharma and has also written for PharmaTimes, and Pharma Pricing and Reimbursement. She has also had her research published in peer review journals including The Patient and Pharmacoeconomics.
Nick Meadows (5-7 Nov 2018)
Nick Meadows has nearly 10 years of experience working in the life sciences industry as a management consultant, technology transfer analyst and medical research scientist. In 2016 he joined Strategy& (part of the PwC network) where he is supporting clients within the pharmaceutical industry address strategic and operational challenges in development and commercial functions.
As a consultant he has managed engagements across research and development and commercial functions of the life sciences and pharmaceutical industry. In the past 5 years his work has spanned major transformational projects in clinical operations and research and development, to asset level strategy through direct engagement with program teams and commercial leads. In his former role at Kinapse (2011 – 2016) he led the market access service line where he supported clients optimise pricing and reimbursement outcomes for launching and development products.
In addition he has collaborated with regulators, policy makers and healthcare practitioners to provide recommendations to accelerate the development of personalised medicines. He has also developed a deep understanding of the biosimilars landscape.
He holds an MBA from Saïd Business School, University of Oxford, and a PhD and BSc (Hons) in Molecular Biology from University of Queensland, Brisbane, Australia.
|5-7 Nov 2018|
|5-7 Nov 2018||Rembrandt Hotel, London||GBP 1,799.00
+ VAT @ 20.00%
|14-16 May 2019|
|14-16 May 2019||Rembrandt Hotel, London||GBP 1,799.00
+ VAT @ 20.00%
|4-6 Nov 2019|
|4-6 Nov 2019||Venue not yet confirmed||
+ VAT @ 20.00%